Emerald Advisers’s Kyntra Bio KYNB Stock Holding History

Emerald Advisers’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12,655	Closed	-$19.2M	–	254
2018 Q3	$19.2M	Sell	12,655 -2,012	-14%	-$3.1M	0.71%	64
2018 Q2	$23M	Buy	+14,667	New	+$19.1M	0.87%	41

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Emerald Advisers's KYNB Position: Q4 2018 in Review

Emerald Advisers sold out of Kyntra Bio (KYNB) in Q4 2018, closing a stake of 12,655 shares — an estimated $19.2M sold.

Emerald Advisers first reported a position in KYNB in Q2 2018 and held it in 2 quarters. The position peaked at $23M in Q2 2018. 201 funds tracked by Wall St. Rank hold KYNB as of Q4 2018.

Emerald Advisers reported no remaining Kyntra Bio position as of Q4 2018 after selling out during the quarter.
Emerald Advisers sold 12,655 Kyntra Bio shares in Q4 2018, an estimated $19.2M.
Emerald Advisers first reported a position in Kyntra Bio in Q2 2018 and held it in 2 quarters.
Emerald Advisers's Kyntra Bio position peaked at $23M in Q2 2018.
201 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2018.

Based on Emerald Advisers's 13F filing for Q4 2018, filed 30 Jan 2019.